Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070889 · ClinicalTrials.gov registry record
Brain Cell Injury in Patients With A First Episode of Psychosis
A clinical trial, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- 30
- Enrollment target
NCT00070889: Completed study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00070889 is a clinical trial that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070889 has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-08 |
What the finished NCT00070889 record still lists
NCT00070889 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00070889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00070889 about?
NCT00070889 is a clinical study titled "Brain Cell Injury in Patients With A First Episode of Psychosis". Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.
What is the current status of trial NCT00070889?
This trial is currently completed. The enrollment target is 30 participants. The study started on 1999-09. Estimated completion is 2004-08.
Who is sponsoring clinical trial NCT00070889?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia